alitative aspects of the item, including, among other things (i) its size and nature, (ii) whether or not it relates to our ongoing business operations, and (iii) whether or not we expect it to occur as part of our normal business on a regular basis. For purposes of determining non-GAAP net income, the asset impairment is excluded.
VIROPHARMA INCORPORATEDSelected Financial InformationSelected Consolidated Balance Sheet DataSeptember 30,December 31,(in thousands)
20112010(unaudited)AssetsCurrent assets:Cash and cash equivalents
$
340,553$
426,732Short-term investments
119,80678,439Inventory
64,38754,388Total current assets
620,434633,141Intangible assets, net
595,321619,712Total assets
1,254,7481,287,574Liabilities and Stockholders’ EquityTotal current liabilities
$
88,855$
72,122Deferred tax liabilities
166,889176,111Long-term debt
151,456145,743Total liabilities
409,266396,439Total stockholders’ equity
845,482891,135Total liabilities and stockholders’ equity
1,254,7481,287,574 Nine Months Ended September 30,September 30,Statement of Cash Flows:20112010(in thousands)
(unaudited)Net cash provided by operating activities
$
21,567$
37,427Net cash used in investing activities
(52,213)(86,995)Net cash (used in) provided by financing activities
(154,768)1,715
'/>"/>
SOURCE ViroPharma Incorporated Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 Related medicine technology :1.
ViroPharma to Release 2011 Third Quarter Financial Results on October 27, 20112.
ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia3.
ViroPharma Announces Additional Securities Repurchase Program4.
ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)5.
ViroPharmas Buccolam® (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures6.
ViroPharma to Participate in the Stifel Nicolaus 2011 Healthcare Conference7.
ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union8.
ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)9.
ViroPharma to Participate in the Jefferies 2011 Global Healthcare Conference10.
ViroPharma Launches Swell, an Original Documentary Chronicling the Lives of People Living with Hereditary Angioedema11.
ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)